Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 10/20 | 0.65 |
| ▸ | GSK3B | P49841 | 9/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.65 |
| ▸ | CSNK1D | P48730 | 8/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.65 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 9/20 | 0.58 |
| ▸ | CDK2 | P24941 | 8/20 | 0.58 |
| ▸ | CDK1 | P06493 | 7/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 6/20 | 0.55 |
| ▸ | PLK4 | O00444 | 6/20 | 0.55 |
| ▸ | AURKA | O14965 | 6/20 | 0.55 |
| ▸ | PRKACA | P17612 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050864 | 0.86 | ICAM1 (0.68) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL7057944 | 0.84 | PIM1 (0.80) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL7060310 | 0.84 | GSK3A (0.78) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL829818 | 0.83 | SLC9A1 (0.52) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL7051662 | 0.82 | ICAM1 (0.78) | ICAM1SELECDK8VCAM1CCNC | |
| SCHEMBL660155 | 0.76 | CSNK1D (0.63) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL30744198 | 0.76 | CSNK1D (0.63) | GSK3AGSK3BDYRK1ACSNK1DAURKB | |
| SCHEMBL23795896 | 0.75 | MYC (0.45) | KDRMAP4K4CYP11B1CYP11B2 | |
| SCHEMBL15697487 | 0.74 | PTPN2 (0.47) | DYRK1A | |
| SCHEMBL7934399 | 0.74 | GSK3A (0.78) | GSK3AGSK3BDYRK1ACSNK1DAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | claimed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | claimed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | claimed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | GSK3A 3245/4885GSK3B 3044/4885DYRK1A 4879/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | GSK3A 3245/4885GSK3B 3044/4885DYRK1A 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.